Navigating treatment choices with your loved one can be overwhelming, so it's important to find support for yourself too.
Here you will find some tips to help look after your emotional well-being, and resources to support you.
Be sure to take time to care for your own health and well-being, with the following tips in mind:
Set aside time for yourself to relax
Don’t be afraid to ask for help, and accept it when it’s offered
Join a support group, in person or online
These organizations offer information and support for caregivers supporting people living with wet AMD.
The National Alliance for Caregiving
An organization committed to helping the families and friends of those with health care needs through research, advocacy, and innovation.
A support organization with the purpose of improving the quality of life for caregivers and those who receive care.
A publication dedicated to providing information, support, and guidance for families and professional caregivers.
This information is provided as a resource for you. We do not endorse or show preference for any particular organization. The organizations in this list are not the only ones that might be able to help you.
Patient and their caregiver have been compensated by Genentech. Patient experiences may vary.
Please see the videos for more information about side effects, including the risk of endophthalmitis.
If your retina specialist determines that it is necessary, you may need an anti-VEGF injection in the gel-like part of the SUSVIMO-treated eye (intravitreal) before your next refill.
YOUR LOVED ONE'S CONVERSATION GUIDE
Ask your loved one to answer a few questions to get their personalized conversation guide. Ask a retina specialist if SUSVIMO is right for them.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
SUSVIMO [package insert]. South San Francisco, CA: Genentech, Inc; 2022.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2019;126:1141-1154.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
SUSVIMO Initial Fill and Implant Procedure Instructions for Use. Genentech, Inc. 2022.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Monés J, Gune S, Maia M, et al. Pharmacokinetic profile of the port delivery system with ranibizumab in the phase 3 Archway trial. Presented at 21st EURETINA Congress, September 9-12, 2021.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Ranade SV, Wieland MR, Tam T, et al. The port delivery system with ranibizumab: a new paradigm for long-acting retinal drug delivery. Drug Delivery. 2022;29(1):1326-1334.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
Holekamp NM, Campochiaro PA, Chang MA, et al; Archway Investigators. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295-307.
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
A phase III study to evaluate the port delivery system with ranibizumab compared with monthly ranibizumab injections in participants with wet age-related macular degeneration. ClinicalTrials.gov identifier: NCT03677934. Updated July 22, 2021. https://clinicaltrials.gov/ct2/show/NCT03677934
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Wykoff CC; Archway Investigators. 2-year outcomes from the phase 3 Archway trial: management of neovascular age-related macular degeneration using the port delivery system with ranibizumab (PDS). Presented at Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 – Virtual Edition, February 11-12, 2022.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Data on file. Genentech, Inc. 2021.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
Chang MA, Kapre A, Kaufman D, et al. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmology. Published online June 16, 2022.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.